Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Foviscu
- Development stage
- Phase 3
- Lead developer
- Wockhardt
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
**Foviscu (WCK 4282)** is a novel antibiotic developed by Wockhardt for the empiric treatment of serious gram-negative bacterial infections, including complicated urinary tract infections (cUTI), hospital-acquired bacterial pneumonia (HABP), and ventilator-associated bacterial pneumonia (VABP). It targets difficult-to-treat pathogens such as those producing extended-spectrum beta-lactamases (ESBL), with a Phase 3 global clinical trial comparing it to meropenem ongoing and expected to complete in FY 2025-26, positioning it as a potential first-line option where current treatments are limited.[2][3][4][7][8][9][10]
- Brand names
- Foviscu
02
Targets
Class A BL (Class A beta-lactamase)
Beyond the preview
Go deeper on Foviscu.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Foviscu.